EuropaBio submission: Pharmaceutical Sector Inquiry

EuropaBio comments for the European Commission stakeholder consultation on the Pharmaceutical Sector Inquiry Preliminary Report (ref 39514)

EuropaBio  welcomes the Commission’s recognition of the essential nature of intellectual property protection for investment and innovation. However, we regret that the report adopts what could be perceived to be an accusatory tone against the innovator industry that risks creating major damage to the reputation of the entire sector, including the biotechnology-based companies and the innovation process. We believe our concerns in relation to the report’s views on the patent system would be shared by other innovation lead industry sectors that rely on secure intellectual property protection as the foundation for their investments in bringing new products to market.